Skip to content

Study of the Effects of a New Infant Formula Supplemented With a Probiotic Over the Corporal Composition of Infants

The Effect of a New Newborn Formula Over the Corporal Composition: a Randomized Multicentric Clinical Trial

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05303077
Enrollment
210
Registered
2022-03-31
Start date
2019-02-11
Completion date
2020-11-25
Last updated
2022-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy

Keywords

Infant formula, body composition, safety

Brief summary

This is a multicentric, randomized, blinded, controlled trial to study the effects of a new infant formula on the changes in the newborn body composition over time: weight gain, anthropometric data, incidence of infections, digestive tolerance (flatulence, vomiting and regurgitation), feces (consistency and frequency), behavior (restlessness, colic, nocturnal awakenings), count of probiotic strains of the intestinal microbiota in feces, safety and tolerability of the investigational products (measured as number, frequency and severity of adverse events in all branches of the study)

Interventions

DIETARY_SUPPLEMENTNutribén Innova® 1

Infants are fed solely with infant formula supplemented with an inactive probiotic and omega 3 fatty acids over the first 6 months of their life, from then on the infants are fed with the study formula and the usual supplementary food, recommended to the baby's

DIETARY_SUPPLEMENTNutribén®

Infants are fed solely with infant formula over the first 6 months of their life, from then on the infants are fed with the study formula and the usual supplementary food, recommended to the baby's age.

DIETARY_SUPPLEMENTBreastfeed

Infants are breastfeeding solely over the first 6 months of their life, from then on the infants are fed as recommended by their caregiver, as if they are not participating in a research study.

Sponsors

Fundación Teófilo Hernando, Spain
CollaboratorOTHER
Biopolis S.L.
CollaboratorINDUSTRY
Alter Farmacia, S.A.
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
DOUBLE (Subject, Investigator)

Masking description

The 2 infant formula arms are blinded for the participant, investigator and data analyst. The 3rd arm is an open control group conformed by breastfeed infants

Eligibility

Sex/Gender
ALL
Age
15 Days to 25 Days
Healthy volunteers
Yes

Inclusion criteria

* Healthy children. Both sex. * Full term infants (between 37 and 42 weeks of pregnancy). * Birth weight between 2500 g- 4500 g. * Single birth babies. * BMI of the mothers before the pregnancy between 19 y 30 kg/m2.

Exclusion criteria

* Body weight lower than the 5th percentile for their gestational age. * Cow's milk protein allergy and/or lactose allergy. * Administration of antibiotics 7 days prior inclusion. * Congenital disease or malformation that may affect the infant growth rate. Population Description: The study population are newborns selected from primary care clinics in Spain. Sampling Method: Not applicable * Metabolic disease or disorders. * Significant prenatal disease and/or serious postnatal disease before recruitment. * Underage parents. * Diabetic mother. * Born from a drug abuse mother (who use abuse drugs during pregnancy). * Parents cannot comply with study procedures. * Subject included or that have been included in other clinical trial since his/her birth day.

Design outcomes

Primary

MeasureTime frameDescription
Weight gain at 6 months6 months after the beginning of the studyMeasure of weight gain by grams/day between the first visit and month 6

Secondary

MeasureTime frameDescription
Length gain21 days, 2, 4, 6 and 12 monthsMeasure of the infant's length gain over time in cms
Head circumference gain21 days, 2, 4, 6 and 12 monthsMeasure of the increase of the head circumference over time in cms
Tricipital Skin fold development4, 6 and 12 monthsMeasurement of the development of tricipital skin fold, in cms, measured using a skinfold caliper
Subscapular skin fold develompent4, 6 and 12 monthsMeasurement of the development of subscapular skin fold, in cms, measured using a skinfold caliper
Mean arm circumference4, 6 and 12 monthsMeasure of arm circumference over time in cms.
Feces features consistency21 days, 2, 4, 6 and 12 monthsDescription of the consistency of baby's feces features, according to their parent's perception, on a qualitative scale: soft, hard, liquid, normal, semiliquid, pasty. The analysis includes the number of feces in each group and the overall frequency by study arm and visit.
Feces features number of bowel movements21 days, 2, 4, 6 and 12 monthsNumber of bowel movements per day sorted by study group
Digestive tolerance4, 6 and 12 monthsThe digestive tolerance will be assessed as adequate, constipation, flatulence, vomit or other distresses, which are a heterogeneous group that includes various affections as diarrhea, abdominal pain, irritability, constipation, regurgitation or colic. The analysis includes the overall number and the frequency sorted by study arm.
weight at 21 days, 2, 4, 6 and 12 months21 days, 2, 4, 6 and 12 monthsMeasure of weight gain by grams
intestinal microbiota4, 6 and 12 monthsAnalysis of the evolution of the intestinal microbiota of the children over the study. The richness and diversity of the microbiota are analyzed and compared between the study groups.
Evolution of calprotectin levels in feces21 days, 2, 6 and 12 monthsMeasurement of the evolution of calprotectin levels in feces over time
Evolution of IgA levels in feces21 days, 2, 6 and 12 monthsMeasurement of the evolution of IgA levels in feces over time
Evolution lactic acid levels in feces21 days, 2, 6 and 12 monthsMeasurement of the evolution of lactic acid levels in feces over time
Evolution of short-chain fatty acid levels in feces21 days, 2, 6 and 12 monthsMeasurement of the evolution of short-chain fatty acid levels in feces over time
Morbilityover a yearAnalysis of the number and frequency of all adverse events registered during the study by feeding group
Products Tolerabilityover a yearQuantitative variable. The tolerability of the products is assessed as adequate, good, very good, unsatisfactory. The analysis includes the overall number y and the relative frequency by group.
Overall rate of the products2, 4, 6 and 12 monthsQuantitative variable. The parents' subjective rate of the products. The assessment can be, acceptable, good, very good, satisfactory or not satisfactory.
Infant's behavior4, 6 and 12 monthsQualitative variable. The infant's behavior is classified as either good or altered. The total number and the relative frequency by group are included in the analysis.

Countries

Spain

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 19, 2026